Magnussen done at McLaren

McLaren won’t be renewing young Dane’s contract for 2016

Denmark’s Formula 1 hope Kevin Magnussen will not have his contract renewed by McLaren for next season, according to Autosport.

Autosport revealed, however, that the young Dane could very well have a future in Formula 1 and is one of three drivers being considered for Lotus’s second seat alongside Pastor Madonaldo.

Magnussen first joined British racing team McLaren in 2012 and swiftly rose through its ranks.

READ MORE: Magnussen out as McLaren go with Button

Sterling debut
He was first part of the team’s talent program before graduating to the Formula 1 team where he finished second on his debut at the 2014 Australian Grand Prix.

But this year, the Dane was demoted to reserve driver following the arrival of Fernando Alonso and he had looked poised to remain so in 2016.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.